To Our New Jersey Life Sciences Community:
Welcome to another edition of the Weekender.
Congratulations to four New Jersey companies that received Food and Drug Administration (FDA) approvals. These wonderful accomplishments shine a positive light on the dynamic life sciences ecosystem in New Jersey.
We can’t wait to share more of your positive news throughout the year.
- Actavis plc, a BioNJ Member located in Parsippany, announced that VIBERZI (eluxadoline) was approved by the FDA as a twice-daily, oral treatment for adults suffering from irritable bowel syndrome with diarrhea (IBS-D).
- Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval for Xifaxan 550 mg for the treatment of IBS-D in adults.
- Janssen Pharmaceuticals, Inc., a BioNJ Member located in Titusville, received FDA approval under priority review the New Drug Application (NDA) for the three-month, long-acting atypical antipsychotic INVEGA TRINZA.
- The FDA has approved Eli Lilly and Company’s, a BioNJ Member located in Bridgewater, Humalog 200 units/mL KwikPen (insulin lispro 200 units/mL; U-200), a pre-filled pen containing a concentrated formulation of Lilly’s rapid-acting insulin Humalog (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes.
Click here for this week’s Weekender.